Prescribing information


Facilitate monitoring of KISQALI patients with the Your Choice programme.

Facilitate monitoring of KISQALI patients with the Your Choice programme.

The Your Choice programme can help facilitate monitoring of KISQALI patients in day-to-day practice

  • Monitor your patients in the COMFORT of their home
  • CONFIDENCE in a service tailored to your needs
  • Reduce COST through fewer hospital visits

Patients enrolled onto Your Choice with KISQALI will be assigned a dedicated nurse who will provide support to complement and enhance existing support from their NHS clinical team. Assistance is offered with monitoring.

This programme is offered for the first 6 months of treatment when support may be required most. In addition, the monitoring support will be provided at a location which is convenient for your patient, i.e. at home or work.


Diagram depicting a dedicated nurse and the other components of the Your Choice with KISQALI programme


Benefits for you and your patients

  • For you: alleviates pressures during clinic by taking bloods and performing ECG assessments outside of hospital appointments
  • For your patients: reduces logistical challenges so patients may not have to come to clinic as often or for as long



For more information on the Your Choice programme, download the guide for HCPs or contact a Novartis representative.


ECG, electrocardiogram; HCP, healthcare professional.

Indication: KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.1


  1. KISQALI® (ribociclib) Summary of Product Characteristics.
Rate this content: 
No votes yet
HCP20-C020 July 2020.

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]